Literature DB >> 30165636

Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study.

Peter E Penson1, D Leann Long2, George Howard2, Peter P Toth3,4, Paul Muntner5, Virginia J Howard5, Monica M Safford6, Steven R Jones3, Seth S Martin3, Mohsen Mazidi7, Alberico L Catapano8, Maciej Banach9,10,11.   

Abstract

Aims: Recent findings have demonstrated the important contribution of inflammation to the risk of cardiovascular disease (CVD) in individuals with optimally managed low density lipoprotein cholesterol (LDL-C). We explored relationships between LDL-C, high sensitivity C-reactive protein (hs-CRP), and clinical outcomes in a free-living US population. Methods and results: We used data from the REasons for Geographical And Racial Differences in Stroke (REGARDS), and selected individuals at 'high risk' for coronary events with a Framingham Coronary Risk Score of ≥10% or atherosclerotic cardiovascular disease (ASCVD) risk ≥7.5% in order to explore relationships between low LDL-C [<70 mg/dL (1.8 mmol/L) in comparison to ≥70 mg/dL (1.8 mmol/L)]; hs-CRP <2 compared with ≥2 mg/L and clinical outcomes [all-cause mortality, incident coronary heart disease (CHD), and incident stroke]. To assess the association between the LDL-C and hs-CRP categories and each outcome, a series of incremental Cox proportional hazards models were employed on complete cases. To account for missing observations, the most adjusted model was used to interrogate the data using multiple imputation with chained equations (MICE). In this analysis, 6136 REGARDS high-risk participants were included. In the MICE analysis, participants with high LDL-C (≥70 mg/dL) and low hs-CRP (<2 mg/L) had a lower risk of incident stroke [hazard ratio (HR) 0.69, 0.47-0.997], incident CHD (HR 0.71, 0.53-0.95), and CHD death (HR 0.70, 0.50-0.99) than those in the same LDL-C category high hs-CRP (≥2 mg/L). In participants with high hs-CRP (≥2 mg/dL), low LDL-C [<70 mg/dL (1.8 mmol/L)] was not associated with additional risk reduction of any investigated outcome, but with the significant increase of all-cause mortality (HR 1.37, 1.07-1.74). Conclusions: In this high-risk population, we found that low hs-CRP (<2 mg/L) appeared to be associated with reduced risk of incident stroke, incident CHD, and CHD death, whereas low LDL-C (<70 mg/dL) was not associated with protective effects. Thus, our results support other data with respect to the importance of inflammatory processes in the pathogenesis of CVD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30165636      PMCID: PMC6195947          DOI: 10.1093/eurheartj/ehy533

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  40 in total

1.  Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

Authors:  Jennifer G Robinson; Robert S Rosenson; Michel Farnier; Umesh Chaudhari; William J Sasiela; Laurence Merlet; Kathryn Miller; John J P Kastelein
Journal:  J Am Coll Cardiol       Date:  2017-02-07       Impact factor: 24.094

2.  Lipids and stroke: looking for risk in all the wrong places?

Authors:  George Howard; David C Goff
Journal:  Ann Neurol       Date:  2011-04       Impact factor: 10.422

3.  What is the association of lipid levels and incident stroke?

Authors:  Stephen P Glasser; Aleena Mosher; George Howard; Maciej Banach
Journal:  Int J Cardiol       Date:  2016-06-23       Impact factor: 4.164

4.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.

Authors:  Antonio J Vallejo-Vaz; Michele Robertson; Alberico L Catapano; Gerald F Watts; John J Kastelein; Chris J Packard; Ian Ford; Kausik K Ray
Journal:  Circulation       Date:  2017-09-06       Impact factor: 29.690

7.  Adiposity, inflammation, and risk for death in black and white men and women in the United States: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Authors:  Susan G Lakoski; Anh H Le; Paul Muntner; Suzanne E Judd; Monika M Safford; Deborah A Levine; George Howard; Mary Cushman
Journal:  J Clin Endocrinol Metab       Date:  2011-03-23       Impact factor: 5.958

Review 8.  Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

Authors:  Manfredi Rizzo; Marcin Barylski; Ali A Rizvi; Giuseppe Montalto; Dimitri P Mikhailidis; Maciej Banach
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.

Authors:  Kausik K Ray; Henry N Ginsberg; Michael H Davidson; Robert Pordy; Laurence Bessac; Pascal Minini; Robert H Eckel; Christopher P Cannon
Journal:  Circulation       Date:  2016-10-24       Impact factor: 29.690

View more
  23 in total

1.  Admission Low-Density Lipoprotein Cholesterol Stratified by Circulating CD14++CD16+ Monocytes and Risk for Recurrent Cardiovascular Events Following ST Elevation Myocardial Infarction: Lipid Paradox Revised.

Authors:  Shaozhuang Dong; Wenjie Ji; Shan Zeng; Jun Miao; Lifang Yan; Xinlin Liu; Junxiang Liu; Xin Zhou; Qing Yang
Journal:  J Cardiovasc Transl Res       Date:  2020-06-18       Impact factor: 4.132

Review 2.  The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events.

Authors:  Serban Maierean; Richard Webb; Maciej Banach; Mohsen Mazidi
Journal:  Eur Heart J Open       Date:  2022-06-14

3.  Cardiovascular risk and metabolic profile of Polish citizens from Lower Silesia. First signs of metabolic crisis?

Authors:  Lukasz Kozera; Wiktor Kuliczkowski; Elzbieta Gocek
Journal:  Arch Med Sci       Date:  2020-10-14       Impact factor: 3.707

4.  The association and joint effect of serum cholesterol, glycemic status with the risk of incident cancer among middle-aged and elderly population in china cardiometabolic disease and cancer cohort (4C)-study.

Authors:  Mian Li; Jieli Lu; Jing Fu; Qin Wan; Tiange Wang; Yanan Huo; Yu Xu; Min Xu; Zhiyun Zhao; Yuhong Chen; Shuangyuan Wang; Guijun Qin; Yingfen Qin; Ruying Hu; Xulei Tang; Guixia Wang; Feixia Shen; Zuojie Luo; Li Chen; Qing Su; Xuefeng Yu; Li Yan; Gang Chen; Zhengnan Gao; Yinfei Zhang; Chao Liu; Youmin Wang; Shengli Wu; Tao Yang; Qiang Li; Yiming Mu; Jiajun Zhao; Lulu Chen; Lixin Shi; Guang Ning; Yufang Bi; Hongyang Wang; Weiqing Wang
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

5.  Comparison of low-density lipoprotein cholesterol level calculated using the modified Martin/Hopkins estimation or the Friedewald formula with direct homogeneous assay measured low-density lipoprotein cholesterol.

Authors:  Istvan Reiber; Laszlo Mark; Gyorgy Paragh; Peter P Toth
Journal:  Arch Med Sci       Date:  2020-08-03       Impact factor: 3.318

Review 6.  Clinical approach to the inflammatory etiology of cardiovascular diseases.

Authors:  Massimiliano Ruscica; Alberto Corsini; Nicola Ferri; Maciej Banach; Cesare R Sirtori
Journal:  Pharmacol Res       Date:  2020-05-20       Impact factor: 7.658

7.  Differences in Leukocyte Telomere Length between Coronary Heart Disease and Normal Population: A Multipopulation Meta-Analysis.

Authors:  Xiaofeng Xu; Haochang Hu; Ying Lin; Fangzhong Huang; Huihui Ji; Yin Li; Shaoyi Lin; Xiaomin Chen; Shiwei Duan
Journal:  Biomed Res Int       Date:  2019-05-06       Impact factor: 3.411

Review 8.  The Role of C-reactive Protein in Patient Risk Stratification and Treatment.

Authors:  Ramón Arroyo-Espliguero; María C Viana-Llamas; Alberto Silva-Obregón; Pablo Avanzas
Journal:  Eur Cardiol       Date:  2021-07-07

9.  Alkaline phosphatase-to-albumin ratio as a novel predictor of long-term adverse outcomes in coronary artery disease patients who underwent PCI.

Authors:  Xin-Ya Dai; Ying-Ying Zheng; Jun-Nan Tang; Wei Wang; Qian-Qian Guo; Shan-Shan Yin; Jian-Chao Zhang; Meng-Die Cheng; Feng-Hua Song; Zhi-Yu Liu; Kai Wang; Li-Zhu Jiang; Lei Fan; Xiao-Ting Yue; Yan Bai; Zeng-Lei Zhang; Ru-Jie Zheng; Jin-Ying Zhang
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

10.  The impact of the cumulative burden of LDL-c and hs-CRP on cardiovascular risk: a prospective, population-based study.

Authors:  Jinglin Mo; Zimo Chen; Jie Xu; Anxin Wang; Xia Meng; Xingquan Zhao; Hao Li; Shouling Wu; Yongjun Wang
Journal:  Aging (Albany NY)       Date:  2020-06-16       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.